Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benimetskaya, L.
Right arrow Articles by Gekeler, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benimetskaya, L.
Right arrow Articles by Gekeler, V.
Clinical Cancer Research Vol. 10, 3678-3688, June 1, 2004
© 2004 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Changes in Gene Expression Induced by Phosphorothioate Oligodeoxynucleotides (Including G3139) in PC3 Prostate Carcinoma Cells Are Recapitulated at Least in Part by Treatment with Interferon-ß and -{gamma}

Luba Benimetskaya1, Timo Wittenberger4, C. A. Stein1,2, Hans-Peter Hofmann4, Claudia Weller4, Johnathan C. Lai1,3, Paul Miller5 and Volker Gekeler4

Departments of 1 Medicine, 2 Pharmacology, and 3 Biomedical Engineering, Columbia University, New York, New York; 4 Altana Pharma AG, Konstanz, Germany; and 5 Johns Hopkins University, School of Public Health, Baltimore, Maryland

ABSTRACT

Purpose: G3139 is an antisense bcl-2 phosphorothioate oligodeoxyribonucleotide that is currently being evaluated in Phase III clinical trials in several human cancers. The aim of the present work was to further identify the apparent non-bcl-2-dependent mechanism of this action of this compound in PC3 prostate cancer cells.

Experimental Design: We performed Affymetrix U95A oligonucleotide microarray studies on mRNA isolated from cells treated with G3139 and related oligonucleotides.

Results: Hierarchical clustering revealed the presence of a set of genes of which the expression was elevated on both 1 and 3 days after oligonucleotide treatment. Significantly, the persistence of expression of the up-regulation of these genes, many of which are members of the IFN cascade, was greater for G3139 than for any other oligomer evaluated. Furthermore, many of the genes with the greatest up-regulation of expression are also those of which the expression is up-regulated after treatment of cells with IFNs. Treatment of PC3 cells with either IFN-ß or -{gamma} recapitulated some of the aspects of the molecular and phenotypic changes observed after treatment with a G3139/Lipofectin complex. These include down-regulation of bcl-2 protein expression itself, down-regulation of protein kinase C {alpha} protein expression (but not that of other protein kinase C isoforms), alteration in p21/Waf1/Cip1 protein expression, up-regulation of MHC-I cell surface expression, and profound suppression of cell growth in the absence of a notable increase in cellular apoptosis. However, G3139 (when complexed with Lipofectin) did not induce the up-regulation of expression of either type I or type II IFNs, nor could IFNs be found in conditioned media from treated cells.

Conclusions: Oligonucleotide microarray experiments demonstrated that G3139 could induce elements of the IFN cascade in PC3 cells in vitro. In addition, the cellular phenotype obtained after treatment with exogenous IFN could, at least in part, recapitulate that obtained after G3139 treatment. Nevertheless, the oligonucleotide microarray experiments we performed also demonstrated that there are extremely large qualitative and quantitative differences between the two treatments.




This article has been cited by other articles:


Home page
Genes Dev.Home page
B. Larrivee, C. Freitas, M. Trombe, X. Lv, B. DeLafarge, L. Yuan, K. Bouvree, C. Breant, R. Del Toro, N. Brechot, et al.
Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis
Genes & Dev., October 1, 2007; 21(19): 2433 - 2447.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. D. Mocanu, K. W. Yip, J. Skliarenko, W. Shi, P. Busson, K.-W. Lo, C. Bastianutto, and F.-F. Liu
Imaging and Modulating Antisense Microdistribution in Solid Human Xenograft Tumor Models
Clin. Cancer Res., October 1, 2007; 13(19): 5935 - 5941.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Benimetskaya, K. Ayyanar, N. Kornblum, D. Castanotto, J. Rossi, S. Wu, J. Lai, B. D. Brown, N. Popova, P. Miller, et al.
Bcl-2 Protein in 518A2 Melanoma Cells In vivo and In vitro.
Clin. Cancer Res., August 15, 2006; 12(16): 4940 - 4948.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. C. Lai, W. Tan, L. Benimetskaya, P. Miller, M. Colombini, and C. A. Stein
A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC
PNAS, May 9, 2006; 103(19): 7494 - 7499.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
D.-T. Chen, J. J. Chen, and S.-j. Soong
Probe rank approaches for gene selection in oligonucleotide arrays with a small number of replicates
Bioinformatics, June 15, 2005; 21(12): 2861 - 2866.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. C. Lai, L. Benimetskaya, A. Khvorova, S. Wu, E. Hua, P. Miller, and C.A. Stein
Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells
Mol. Cancer Ther., February 1, 2005; 4(2): 305 - 315.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Benimetskaya, J. C. Lai, A. Khvorova, S. Wu, E. Hua, P. Miller, L.-M. Zhang, and C. A. Stein
Relative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma Cells
Clin. Cancer Res., December 15, 2004; 10(24): 8371 - 8379.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Hu, G. Bebb, S. Tan, R. Ng, H. Yan, J. R. Sartor, L. D. Mayer, and M. B. Bally
Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non-Small Cell Lung Cancer
Clin. Cancer Res., November 15, 2004; 10(22): 7662 - 7670.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2004 by the American Association for Cancer Research.